Entero Healthcare Solutions valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
Price multiples — at each FY-end close
55.48×———
4.12×———
0.98×———
242.77×———
Enterprise multiples
1.03×———
23.37×———
27.47×———
Yield
1.8%———
0.4%———
Reference — adjusted share basis
₹1,599.00———
₹28.82₹26.44₹21.79₹8.99
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ENTERO₹1,599.00

Entero Healthcare Solutions Ltd.

· Consumer Services
₹ CrorePeersMEDPLUSEMILCRIZACGPPLCMSINFOHEMIPROPBLACKBUCKINOXGREENMcap ₹6,957 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————55.48
P/B————4.12
P/Sales————0.98
Price to Free Cash Flow————242.77
Enterprise Multiples
EV/Sales————1.03
EV/EBITDA————23.37
EV/EBIT————27.47
Yield
Earnings Yield %————1.80
FCF Yield %————0.41
Reference — adjusted share basis
Price (FY-end close, adj.)————1,599.00
EPS (adj.)—8.9921.7926.4428.82
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.